Fundraising Fox

GH Research

NASDAQ: GHRS

2 known investors

GH Research is a clinical-stage pharmaceutical company developing mebufotenin (5-MeO-DMT) based therapies for psychiatric and neurological disorders. Its lead program, GH001, is a pulmonary inhalation formulation being developed for treatment-resistant depression, bipolar II disorder, and postpartum depression.

BiotechDigital HealthMental Health

Investors · 2

Foresite CapitalWest Hollywood
RA CapitalBoston

In the news

GH Research (GHRS) Looks Pricey Following Wider Losses In Its Latest Earnings Report - Simply Wall St Newssimplywall.st · Aug 2026GH Research stock hits all-time high at 31.41 USD By Investing.comng.investing.com · Aug 2026Is GH Research (GHRS) Trading At A Premium To Fair Value?finance.yahoo.com · Aug 2026Is GH Research (GHRS) Fully Valued Following Its Share Price Surge? - Simply Wall St Newssimplywall.st · Aug 2026GH Research (GHRS) Stock Looks Stretched On Its 111% YTD Run - Simply Wall St Newssimplywall.st · Jul 2026Why GH Research (GHRS) Is Up 7.2% After $117.5 Million Follow-On Equity Raise - And What's Next - Simply Wall St Newssimplywall.st · May 2026

Frequently asked questions

What does GH Research do?
GH Research is a clinical-stage pharmaceutical company developing mebufotenin (5-MeO-DMT) based therapies for psychiatric and neurological disorders. Its lead program, GH001, is a pulmonary inhalation formulation being developed for treatment-resistant depression, bipolar II disorder, and postpartum depression.
Who are GH Research's investors?
GH Research's investors include Foresite Capital, RA Capital.